Compare Marvell Technology Inc (MRVL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs GeneDx Holdings Corp — how do they compare? Marvell Technology Inc trades at $231.08 (market cap $211.20B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Marvell Technology Inc is far larger — about 81.9× GeneDx Holdings Corp's market cap, and Marvell Technology Inc pays a 0.1% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MRVL | WGS | |
|---|---|---|
Market Cap | $211.20B | $2.58B |
Sector | Technology | Technology |
52-Week High | $316.43 | $167.51 |
52-Week Low | $66.59 | $34.51 |
Enterprise Value | $212.56B | $2.61B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth with Q2 2026 EPS beating expectations at $0.94 versus $0.934, while management projects revenue reaching $12 billion this fiscal year and $18 billion next year. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $303.11 price target, representing 35% upside potential from current levels.
Marvell's AI-driven growth trajectory presents significant opportunity, though investors face risks from high valuation multiples (P/E 74.02) and competitive pressures in the semiconductor space. The stock's recent 31% pullback from yearly highs offers potential entry point for growth-oriented investors, supported by strong institutional accumulation and positive earnings momentum heading into October's Investor Day event.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
